Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 3.57% 43.50 42.00 45.00 44.00 42.00 42.00 144,523 16:18:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.0 -11.9 - 19

Destiny Pharma PLC Presentation at the Investival Showcase

15/11/2019 7:30am

RNS Non-Regulatory


Destiny Pharma PLC

15 November 2019

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Destiny Pharma to present at the InvEUR$tival Showcase in partnership with Jefferies

Brighton, United Kingdom - 15 November 2019 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti--microbial drugs that address clear commercial opportunities and also address the global problem of anti--microbial resistance (AMR), announces that Neil Clark, Chief Executive Officer of Destiny Pharma, will present at the InvEUR$tival Showcase, in partnership with Jefferies, on 19 November 2019 in London, UK.

About InvEUR$tival Showcase

Returning for its fourth year, LSX's InvEUR$tival Showcase continues and expands upon its exclusive partnership with global investment bank Jefferies, with the showcase co-located with the Jefferies 2019 London Healthcare Conference.

The InvEUR$tival Showcase directly connects life sciences corporates to global capital and offers the opportunity for a greater proportion of private and smaller cap public companies to be a part of the biggest week in European life sciences investment. It provides the opportunity to pitch, profile and connect with investment partners brought together in London by both LSX and Jefferies.

Over the last three years, InvEUR$tival Showcase has welcomed numerous companies across all areas of biotech, medtech and healthtech. Their investor network is particularly interested in innovations in oncology, neurology, infectious diseases, immunology, cardiovascular, musculoskeletal, respiratory and cardiometabolic.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

FTI Consulting

Simon Conway / Victoria Foster Mitchell

+44 (0) 20 3727 1000

finnCap Ltd (Nominated Advisor Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development and commercialisation of novel medicines from its XF Platform that represent a new approach to the treatment of infectious disease. The company's lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post--surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life--threatening infections caused by antibiotic--resistant bacteria, often referred to as "superbugs". Tackling anti--microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

November 15, 2019 02:30 ET (07:30 GMT)

1 Year Destiny Pharma Chart

1 Year Destiny Pharma Chart

1 Month Destiny Pharma Chart

1 Month Destiny Pharma Chart
Your Recent History
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200118 13:58:27